Biontech announces strategic transaction to acquire curevac in public exchange offer

Mainz and tÜbingen, germany, june 12, 2025 (globe newswire) -- biontech se (nasdaq: bntx, “biontech”) and curevac n.v. (nasdaq: cvac, “curevac”) today announced that they have entered into a definitive purchase agreement pursuant to which biontech intends to acquire all of the shares of curevac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mrna”). the all-stock transaction will bring together two highly complementary companies based in germany and will build on biontech's proven track record and established position in the global mrna industry.
BNTX Ratings Summary
BNTX Quant Ranking